(19)
(11) EP 3 102 697 A1

(12)

(43) Date of publication:
14.12.2016 Bulletin 2016/50

(21) Application number: 15702464.7

(22) Date of filing: 02.02.2015
(51) International Patent Classification (IPC): 
C12Q 1/68(2006.01)
(86) International application number:
PCT/EP2015/052081
(87) International publication number:
WO 2015/114146 (06.08.2015 Gazette 2015/31)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 03.02.2014 EP 14153692
04.02.2014 EP 14153786

(71) Applicant: Myriad Genetics, Inc.
Salt Lake City, UT 84108 (US)

(72) Inventors:
  • BRASE, Jan Christoph
    50829 Cologne (DE)
  • KRONENWETT, Ralf
    50829 Cologne (DE)
  • VON MINCKWITZ, Gunter
    50829 Cologne (DE)
  • LOIBL, Sibylle
    50829 Cologne (DE)
  • GADE, Stephan
    50829 Cologne (DE)
  • DENKERT, Carsten
    50829 Cologne (DE)
  • DARB-ESFAHANI, Silvia
    50829 Cologne (DE)
  • SOTIRIOU, Christos
    50829 Cologne (DE)
  • LOI, Sherene
    50829 Cologne (DE)

(74) Representative: dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB 
Deichmannhaus am Dom Bahnhofsvorplatz 1
50667 Köln
50667 Köln (DE)

   


(54) METHOD FOR PREDICTING THE RESPONSE TO AN ANTI-HER2 CONTAINING THERAPY AND/OR CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER